Treatment with Endeavor Biomedicines’ experimental oral therapy ENV-101 (taladegib) improved lung function in people with IPF ...

Is life expectancy still rising? New research shows longevity gains in wealthy nations are slowing, and future generations ...

What is the life expectancy for idiopathic pulmonary fibrosis Explore Diane Ladd’s death cause and her six-year journey with ...

BOSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of inhaled therapies for the treatment of life-threatening pulmonary ...

Pulmonary fibrosis is a deadly disease in which the lungs become thickened and scarred, gradually losing their ability to deliver oxygen to the body. Now, scientists at UC San Francisco have ...

Life expectancy is back to pre-pandemic levels, according to global health research — but mortality rates for teens and young adults are of growing concern. The latest release of The Global Burden of ...

The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis (IPF). This is the first new therapy in more than 10 years to be approved for ...

James Boudreau was diagnosed with cystic fibrosis as a child. The disease comes with immense difficulties, but Boudreau is still looking to challenge himself. Republicans Are Pulling the Plug on ...

More than 10 years after bringing one of the first idiopathic pulmonary fibrosis (IPF) drugs to market, Boehringer Ingelheim is freshening up its leadership in the rare lung disease space with a newly ...

Credit: Boehringer Ingelheim. Nerandomilast reduces the expression of pro-fibrotic growth factors and inflammatory cytokines, commonly overexpressed in IPF. Findings showed nerandomilast led to a ...

What Is Jascayd, and Why Does It Matter? Jascayd (nerandomilast) is a new oral medicine approved to treat idiopathic pulmonary fibrosis (IPF) in adults. IPF is a rare and serious condition that causes ...